EyePoint Pharmaceuticals (NASDAQ:EYPT) Upgraded by Zacks Investment Research to Buy

EyePoint Pharmaceuticals (NASDAQ:EYPT – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Monday, Zacks.com reports. The firm presently has a $10.00 price objective on the stock. Zacks Investment Research‘s target price suggests a potential upside of 3.20% […]

Related Keywords

China ,United States ,Hong Kong ,United Kingdom ,Zurcher Kantonalbank Zurich Cantonalbank ,Fourthought Financial ,Sivida Corp ,Zacks Investment Research ,Eyepoint Pharmaceuticals Company Profile Get Rating ,Cantor Fitzgerald ,Eyepoint Pharmaceuticals ,Citigroup Inc ,Paragon Capital Management Ltd ,Eyepoint Pharmaceuticals Inc ,Hong Kong Ltd ,Get Rating ,Investment Research ,Point Pharmaceuticals ,Thought Financial ,Capital Management Ltd ,Kantonalbank Zurich Cantonalbank ,Kong Ltd ,Point Pharmaceuticals Company Profile ,Nasdaq Eypt ,Eypt ,Medical ,Upgrade ,